News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...
Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster ... be $316.85 for a pack of five pens, 15% below the list price ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added ...
Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...
After years of preparation, Eli Lilly is on the brink of launching ... The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback